[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-attack\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-attack":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,82,120,148,176,202,234,256],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100641326","post-exacerbation-asthma-clinic-telecare-intervention-to-reduce-recurrent-exacerbations-100641326",false,"NCT07629830","Post Exacerbation Asthma Clinic Telecare Intervention to Reduce Recurrent Exacerbations","A Remote Clinic Intervention Following Hospital Discharge for Asthma Exacerbation to Reduce Recurrent Exacerbations","PACT","Inclusion Criteria:\n\n* Presentation to the emergency department with an asthma exacerbation.\n* Ability to complete telephone follow-up and access to a personal e-mail account.\n* Agreement to participate in the study.\n* Written or verbal informed consent according to study group assignment.\n\nExclusion Criteria:\n\n* Uncontrolled cardiac disease.\n* Any other uncontrolled medical condition.\n* Inability to complete telephone follow-up.\n* Pregnancy.\n* Patients lacking decision-making capacity.","ALL","18 Years","75 Years",{"count":21,"type":22},220,"ESTIMATED","INTERVENTIONAL",[25],"NA","Asthma exacerbations leading to emergency department visits or hospitalization are associated with a high risk of recurrent exacerbations, poor disease control, and increased healthcare utilization in the months following discharge. Early specialist follow-up during this vulnerable transition period remains limited, and many patients do not receive optimized long-term asthma management. The purpose of this study is to evaluate whether a structured remote asthma clinic intervention initiated shortly after hospital discharge can reduce recurrent exacerbations and improve asthma-related outcomes compared to standard community care.\n\nThis prospective randomized study will enroll 220 adult patients (18-75 years) presenting to the emergency department at Tel Aviv Sourasky Medical Center with an asthma exacerbation. Participants will be randomly assigned to one of two groups:\n\n1. Intervention group - will undergo two structured remote pulmonology follow-up visits via secure video consultation within 7-21 days and 5 months after discharge, including treatment optimization, inhaler technique assessment, and self-management education.\n2. Control group - will continue standard community care without additional intervention.\n\nAll participants will complete scheduled follow-up assessments over 12 months, including evaluation of exacerbations, asthma control, healthcare utilization, and medication use.",[28,29],"Asthma Acute","Asthma Attack",[31,32,33,34],"Asthma flare-up","Asthma management","remote clinic","pulmonologist","NOT_YET_RECRUITING","2026-06-18",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":22},"2026-07-01",{"date":43,"type":22},"2028-12-31",{"name":45,"class":46},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":18,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":47},"100601896","cost-effective-air-filtration-intervention-in-low-income-housing-to-reduce-asthma-morbidity-100601896","NCT07116460","Cost Effective Air Filtration Intervention in Low-Income Housing to Reduce Asthma Morbidity","Cost Effective Air Filtration Intervention and Particulate Matter Monitoring in Low-Income Housing to Reduce Asthma Morbidity","Inclusion Criteria:\n\n* Age 7-18 years\n* Asthma symptoms in the past 4 weeks\n* Resident in lower-income housing in NYC Northern Manhattan and South Bronx\n\nExclusion Criteria:\n\n* Inability to successfully perform spirometry maneuver or FeNO test\n* Family planning to move in the next year","7 Years",{"count":57,"type":22},55,[25],"This project will investigate the effectiveness of HEPA air cleaners in reducing indoor air pollution and improving asthma morbidity in children living in East Harlem, New York City (NYC). The study will be conducted over a 2-year period.\n\nColumbia University and Little Sisters of the Assumption Family Health Service (LSAFHS) will conduct an intervention study to evaluate the efficacy of using a cost-effective high-capacity high efficiency particulate air (HEPA) filter air cleaner to reduce airborne particulate matter (PM) in the homes of children with asthma and to reduce their asthma morbidity. The study will take place in East Harlem, a low-income neighborhood with high asthma prevalence. It will build on findings from prior Housing and Urban Development Lead and Healthy Homes Technical Studies (HUD LHHTS)-funded research, the experience of LSAFHS installing air cleaners in the homes of asthmatic children, and recent findings demonstrating the effectiveness of home air cleaners in reducing asthma morbidity. The investigators hypothesize that the cost-effective single air cleaner will substantially reduce PM exposure in the homes of asthmatic children and reduce airway inflammation and asthma morbidity. This study will use cutting-edge air sampling technology to continuously quantify and characterize indoor air pollutants in the home for one year, verify and incentivize compliance, and conduct repeated exhaled nitric oxide and pulmonary function tests before and throughout the year after the intervention. This cost-effective intervention can be easily and quickly implemented in homes in low-income, urban communities and easily transferred between homes if families move.",[29,61,62],"Lung Function","Airway Inflammation",[64,65,66,67,68,69,70],"asthma","air cleaner","particulate matter","pm2.5","lung function","airway inflammation","children","RECRUITING","2026-05-29",{"date":74,"type":39},"2026-06-02",{"date":76,"type":39},"2026-01-30",{"date":78,"type":22},"2028-04",{"name":80,"class":81},"Columbia University","OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100623465","boosting-referrals-to-asthma-specialists-for-patients-seen-at-the-emergency-room-for-an-asthma-exacerbation-100623465","NCT07396987","Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","Inclusion Criteria:\n\n* Age ≥18 years\n* Asthma diagnosis ≥1 year\n* Seen in ER for asthma exacerbation\n* Persistent asthma on controller therapy\n* ≥1 asthma exacerbation in prior year\n\nWe will allow for current smokers, vapers and cannabis users as long as they have not been diagnosed with COPD and have a smoking history \\\u003C10 pack-years.\n\nWe will allow for COPD as long as they are:\n\n1. never smokers\u002Fvapers\u002Fcannabis users; or\n2. former or current smokers\u002Fvapers\u002Fcannabis users with normal pulmonary function tests (PFT; FEV1\u002FFVC ratio of \\>70%) within 12 months of enrollment and a smoking history \\\u003C10 pack-years; or\n3. current or former smoker\u002Fvapers\u002Fcannabis users with obstruction on PFTs (FEV1\u002FFVC ratio of \\\u003C70%) but who demonstrate BOTH \\>10% acute bronchodilator reversibility AND a normal diffusing capacity both within 12 months of enrollment (stricter criteria than those used in the PREPARE trial (15) and a smoking history \\\u003C10 pack-years.\n\nExclusion Criteria:\n\n* Patients who have seen an asthma specialist (allergist or pulmonologist) for asthma in the past 2 years\n* Diagnosis of other pulmonary diseases (e.g., COPD, interstitial lung disease, etc.)",{"count":89,"type":22},40,[25],"This study is testing a new way to help adults with asthma get follow up care after an emergency room (ER) visit for an asthma attack. Many people who come to the ER for asthma never see an asthma specialist afterward, even though specialists can offer treatments such as advanced inhalers or biologic medicines that may prevent future attacks.\n\nThe study will compare two approaches. One group will receive a telehealth appointment with an asthma specialist that is scheduled for them before they leave the ER. The other group will receive the usual care, which typically includes a standard referral but no scheduled appointment. All participants will be offered a prescription for standard controller medication at discharge.\n\nThe main question the study aims to answer is whether arranging a telehealth visit directly from the ER increases the number of patients who complete a follow up appointment with an asthma specialist within three months. The study will also look at whether this approach improves asthma control, reduces repeat ER visits, and helps patients better understand and use their asthma medications.\n\nThis research may help identify a practical way to improve access to asthma specialists and reduce the burden of asthma for patients who frequently rely on emergency care.",[29,93,94,95],"Asthma Control","Asthma Exacerbations","Asthma",[64,97,98,99,100,101,102,103,104,105,106,107,108,109,110],"asthma exacerbation","asthma control","inhaled corticosteroid","Long-Acting Beta-Agonist","Long-Acting Muscarinic Antagonist","Emergency Room","Asthma Control Test","Medication Adherence Report Scale for Asthma","Asthma Symptom Utility Index","barriers to care","social determinants of health","access to care","telehealth","telemedicine","2026-05-22",{"date":113,"type":39},"2026-05-26",{"date":115,"type":22},"2026-06",{"date":117,"type":22},"2027-06",{"name":119,"class":81},"Juan Carlos Cardet",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":47},"100572555","wearable-electronic-breath-sound-sensing-device-100572555","NCT06734793","Wearable Electronic Breath Sound Sensing Device","Pilot Study of Wearable Electronic Breath Sound Sensing Device for Monitoring of Breath Sounds in Pediatric Patients With Asthma","WEBSS","Inclusion Criteria:\n\n* Age 6-17 years\n* Diagnosis of persistent asthma\n* Being treated for an acute asthma exacerbation\n* Parent can speak and understand English\n\nExclusion Criteria:\n\n* Unable to provide consent for the study\n* History of prematurity\n* History of other chronic lung conditions - cystic fibrosis, bronchiectasis, or primary ciliary dyskinesia\n* History of latex allergy or allergy to medical tape adhesive\n* Patients currently using another medical device - implanted pacemaker or vagal nerve stimulator or diaphragm pacing device","6 Years","17 Years",{"count":131,"type":22},25,"OBSERVATIONAL","This study will assess the ability of a wearable stethoscope to monitor wheezing in high-risk asthma patients admitted at Children's Healthcare of Atlanta.\n\nThis study is important to assist in the health management of patients with chronic lung diseases that can experience exacerbations leading to their health worsening and requiring hospitalization. The population that will be approached for this study will include 10 pediatric subjects hospitalized at Children's Healthcare of Atlanta for an asthma-related exacerbation. Participants will wear the patches for up to 8 hours on their chest and back wall from their date of consent until their hospital discharge. This may range from the participant taking part in 1 to 14 visits that could last up to 8 hours.",[135,29],"Asthma in Children",[137,138,94],"Hospital admission","Wearable stethoscope","2026-03-22",{"date":141,"type":39},"2026-03-25",{"date":143,"type":39},"2025-02-26",{"date":145,"type":22},"2026-12-31",{"name":147,"class":81},"Emory University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":155,"maxAge":129,"enrollmentInfo":156,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":158,"conditions":159,"keywords":164,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":47},"100602907","remote-monitoring-of-asthma-in-children-and-young-people-100602907","NCT07129616","Remote Monitoring of Asthma in Children and Young People","Remote Monitoring of Asthma in Children and Young People - Reducing Risk of Asthma Attack Using a Connected Patient Approach","Inclusion Criteria:\n\n* Children and Young People with a diagnosis of asthma (coded as asthma or suspected asthma) or a prescription of inhaled corticosteroid in the prior 2 years.\n\nExclusion Criteria:\n\n* Alternative non-asthma diagnosis that would require inhaled steroid\n* cystic fibrosis\n* bronchiectasis\n* primary ciliary dyskinaesia","5 Years",{"count":157,"type":22},900,"The objective of this study is to determine whether healthcare data and remotely collected patient data can accurately predict asthma attacks in children and young people aged 5-17 years. The main outcome is:\n\nwhen using this new system, is there a reduction in asthma attacks compared with a historic average.\n\nThe whole population of children and young people with asthma will have routine healthcare data monitored, with a subset of people with high risk asthma asked to participate in a more detail study involving remotely monitored data.",[160,29,161,162,163],"Asthma Childhood","Remote Monitoring","Risk Assessment","Machine Learning",[165,166],"asthma attack risk reduction","remote monitoring","2026-01-20",{"date":169,"type":39},"2026-01-22",{"date":171,"type":39},"2025-11-20",{"date":173,"type":22},"2027-03-01",{"name":175,"class":81},"University of Edinburgh",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":183,"maxAge":19,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100597012","phase-4-individualizing-treatment-for-asthma-in-primary-care-full-study-100597012","NCT07052942","Individualizing Treatment for Asthma in Primary Care (Full Study)","iTREAT-PC","Inclusion Criteria:\n\n1. A clinical asthma diagnosis for at least 1 year;\n2. 13-75 years of age;\n3. A prescription for an ICS either used regularly, or on an as needed controller, not reliever, schedule - ICS or ICS + LABA or ICS+LABA+LAMA;\n4. A current ACT total score of \\\u003C20 OR an exacerbation requiring 72 hours or more of systemic steroids or a hospitalization of at least 24 hours \\> 30 days and \\\u003C 365 days prior to enrollment;\n5. Able to provide consent (adolescents: assent) in English or Spanish; (i.e., cognitively impaired individuals are deemed not to be able to provide consent and thus do not meet inclusion criteria.);\n6. Patients with a coexisting clinical diagnosis of COPD are eligible if they meet any one of the following criteria:\n\n   (i) Never smoker without secondary lung disease causing airway obstruction. (ii) Current or former smoker with obstruction on PFTs, but normal diffusing capacity of the lungs for carbon monoxide (DLCO) in the past 24 months.\n7. Patients on medications that may interact with azithromycin but are not totally excluded may be enrolled if they agree to a cardiac rhythm strip after consent and prior to randomization (or have an ECG within the prior 24 months as a baseline assessment) and a repeat rhythm strip after one week if randomized to one of the azithromycin arms of the study.\n\nExclusion Criteria:\n\n1. Another family member living in the same household already enrolled in study;\n2. Life expectancy \\\u003C1 year (operationalized by the question to the patient's asthma care clinician \"Would you be surprised if this person died in the next 12 months? If yes - include, if no - exclude);\n3. No ICS prescribed for the individual (does not have to be using the ICS inhaler);\n4. Active treatment for hematological or solid organ cancer other than basal cell or skin squamous cell cancer (if participant is \\> 12 months out from original therapy and may be on a cancer maintenance drug that is not otherwise contraindicated they are eligible for the study);\n5. Allergy to macrolides or conditions for which macrolide administration may possibly be hazardous (e.g., acute or chronic hepatitis, cirrhosis, or other liver disease; end-stage renal disease; uncorrected hypokalemia or hypomagnesemia; clinically significant bradycardia; or history of prolonged cardiac repolarization and QT interval or evidence of prolonged cardiac repolarization on rhythm strip and QT interval or torsades de pointes);\n6. On daily or every other day oral steroids for any reason;\n7. A course of systemic steroids for an asthma exacerbation or an overnight hospitalization for an asthma exacerbation in the past month (can wait and re-check eligibility after one month);\n8. Currently on R-ICS or any antibiotic therapy expected to last more than 30 days. If on antibiotics less than 30 days, individual can enroll after they have stopped their current antibiotic for 72 hours. Individuals on biologics can be enrolled if they have been on a stable dose for \\> 6 months and meet the ACT or exacerbation criteria as well as all other criteria after being on the stable does of the biologic.\n9. On a medication with known risk (i.e., that is associated with prolonged QT and associated with torsades de pointes even when taken as recommended)- absolute contraindication to eligibility- Full lists in Appendix B;\n10. Specified medications for which close monitoring has been recommended in the setting of macrolide administration (digoxin, warfarin, theophylline, ergotamine or dihydroergotamine, cyclosporine, hexobarbital, phenytoin or nelfinavir).","13 Years",{"count":185,"type":22},3200,[187],"PHASE4","While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects.\n\nThis study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced \"Ricks,\" and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.",[95,29,94],[191],"Intervention\u002FTreatment","2025-10-28",{"date":194,"type":39},"2025-10-29",{"date":196,"type":39},"2025-08-01",{"date":198,"type":22},"2029-11-15",{"name":200,"class":46},"DARTNet Institute",13,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100601589","phase-2-nebulized-ketamine-plus-standard-care-vs-standard-care-alone-in-moderate-to-severe-asthma-exacerbations-100601589","NCT07112456","Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations","Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations: A Randomized Clinical Trial (KET-AIR Trial)","KET-AIR","Inclusion Criteria:\n\n1. Adults aged 18 years or older presenting to the Emergency Department with a clinical diagnosis of moderate to severe asthma exacerbation based on SIGN (Scottish Intercollegiate Guidelines Network) criteria.\n2. PEFR between 33% and 75% of predicted value or personal best, as measured using a peak flow meter.\n3. Stable vital signs as deemed by the treating physician\n4. Alert and oriented, able to understand the study purpose and provide informed consent.\n5. Not requiring immediate advanced airway intervention, including intubation or emergency non-invasive ventilation.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or allergy to ketamine or any component of the nebulized solution.\n2. History of psychosis, schizophrenia, or other severe uncontrolled psychiatric disorders.\n3. Uncontrolled hypertension, defined as systolic BP \\> 180 mmHg or diastolic BP \\> 110 mmHg on two consecutive readings at least 5 minutes apart, despite initial ED management.\n4. Hemodynamic instability, including persistent hypotension (SBP \\\u003C 90 mmHg) or tachyarrhythmias requiring urgent treatment.\n5. Significant chronic lung disease, including:\n\n   * COPD with frequent exacerbations or baseline FEV₁ \\\u003C 50% predicted\n   * Interstitial lung disease (ILD)\n   * Clinically significant bronchiectasis with baseline productive cough or infection\n6. Pregnancy or currently breastfeeding.\n7. Home BiPAP use or requirement for non-invasive ventilation (e.g., BiPAP\u002FCPAP) during the ED visit (Note: isolated home CPAP for sleep apnea without daytime symptoms is acceptable).\n8. Current intubation or imminent need for mechanical ventilation based on clinical judgment.\n9. Severe cardiac disease, including decompensated heart failure, recent myocardial infarction (\\\u003C6 weeks), or known severe valvular disease.\n10. Any other medical, surgical, or psychiatric condition that in the opinion of the investigator would place the patient at undue risk from study participation or interfere with the interpretation of study results.",{"count":211,"type":22},100,[213],"PHASE2","The goal of this clinical trial is to learn if nebulized ketamine helps treat moderate to severe asthma attacks in adults in the emergency department. It will also learn about the safety of ketamine when inhaled through a nebulizer.\n\nThe main questions it aims to answer are:\n\n* Does nebulized ketamine improve breathing more than standard treatment alone?\n* What side effects, if any, do participants experience after receiving nebulized ketamine?\n\nResearchers will compare nebulized ketamine to a placebo (a saltwater mist with no medication) to see how well it works and how safe it is.\n\nParticipants will:\n\n* Receive either nebulized ketamine or a placebo mist, along with standard asthma treatment\n* Have their breathing checked before and after treatment using a peak flow meter\n* Be monitored for 60 minutes and have their symptoms, vital signs, and any side effects recorded",[28,29,94],[95,217,218,219,220,221,222,223,224,225],"Asthma, Severe","Asthma Exacerbation","Emergency Treatment","Ketamine","Ketamine, Nebulized","Bronchodilator Agents","Randomized Controlled Trial","Peak Expiratory Flow Rate","Safety and Efficacy",{"date":227,"type":39},"2025-08-08",{"date":229,"type":22},"2026-09-01",{"date":231,"type":22},"2029-08-31",{"name":233,"class":46},"Oman Medical Speciality Board",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":47},"100545088","remote-patient-monitoring-solution-for-chronic-respiratory-disease-management-100545088","NCT06377345","Remote Patient Monitoring Solution for Chronic Respiratory Disease Management","Inclusion Criteria:\n\n* Diagnosis of asthma\n* Pediatric patients (age 7 to 17), adult patients (age 18 and above\n* Have an asthma exacerbation on the day of visit\n* Be willing to use the AeviceMD device\n* Has a smart phone to download the application that is paired with Aevice\n* Has wireless fidelity (WIFI) connection to use with Aevice\n* English speaking\n\nExclusion Criteria:\n\n* No capacity for consent\n* Concurrent chronic obstructive pulmonary disease (COPD)","90 Years",{"count":242,"type":22},180,[25],"Aim: To evaluate the use of AeviceMD Monitoring System (AeviceMD) asthma in reducing acute exacerbation.\n\nMethodology: Using a randomized controlled trial design, this project aims evaluate the effectiveness of AeviceMD in improving patients' outcomes in terms of reducing exacerbation, healthcare utilization, improving quality of life, self-efficacy, and cost effectiveness. Paediatric patients above age 7 and adults will be recruited. The data follow-up period is 3 months. It will also evaluate the usability of the device from both patients' and clinicians' perspective. 180 patients (124 adults, 56 pediatrics) and 120 clinicians will be recruited.\n\nImportance of study: This study will evaluate if the AeviceMD can help improve disease management and reduce recurrence of asthma exacerbation.\n\nPotential benefits and risk: AeviceMD allows for remote monitoring and tracking of patients' lung sounds, which could be used by patients to monitor their lung condition and prevent an episode of exacerbation or worsening exacerbations culminating in an admission which who further utilize already limited healthcare resources. An exacerbation is an episode of severe shortness of breath, cough, and chest tightening which warrants a visit to a healthcare institution. Through self-monitoring, patients can be empowered to self-manage their asthma, with aid of the asthma action plan which is given to all patients with asthma. AeviceMD can also help provide clinicians with patients' objective lung data. In the primary care setting, care is also fragmented as patients are often followed-up by a different doctor or healthcare providers. Clinicians have no objective data to track patients, and is dependent on patients' self-report and possible recall bias. There is no expected risk with the use of the device.",[95,29,135,28,246],"Asthma Chronic","2025-05-12",{"date":249,"type":39},"2025-05-15",{"date":251,"type":39},"2024-05-01",{"date":253,"type":22},"2025-12-30",{"name":255,"class":81},"SingHealth Polyclinics",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":17,"minAge":155,"maxAge":129,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":47},"100526614","early-phase-1-timely-administration-of-iv-magnesium-sulfate-in-patients-with-a-moderate-asthma-exacerbation-100526614","NCT06137040","Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation","Inclusion Criteria:\n\n* Ages 5-17 years old\n* Presents to the ED with a respiratory score in the \"Moderate\" range (6\n* Parent(s)\u002FCaregiver(s) speak English\n\nExclusion Criteria:\n\n* Patients with chronic medical conditions including chronic pulmonary disease (other than asthma), cerebral palsy, congenital heart disease, tracheostomy dependent, myasthenia gravis patients\n* Patients who are pregnant\n* Parent(s)\u002FCaregiver(s) do not speak English",{"count":211,"type":22},[264],"EARLY_PHASE1","This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.",[135,29],[97,268,64,269],"magnesium sulfate","asthma attack","2024-12-05",{"date":272,"type":39},"2024-12-06",{"date":274,"type":39},"2023-11-30",{"date":276,"type":22},"2025-05-31",{"name":278,"class":81},"University of Oklahoma"]